virtual
screen
play
signific
role
discoveri
small
molecul
inhibitor
therapeut
target
last
two
decad
variou
ligand
structurebas
virtual
screen
approach
employ
identifi
small
molecul
ligand
protein
interest
approach
often
combin
either
hierarch
parallel
manner
take
advantag
strength
avoid
limit
associ
individu
method
hierarch
combin
ligand
structurebas
virtual
screen
approach
receiv
noteworthi
success
numer
drug
discoveri
campaign
hierarch
virtual
screen
sever
filter
use
ligand
structurebas
approach
sequenti
appli
reduc
larg
screen
librari
number
small
enough
experiment
test
review
focu
differ
hierarch
virtual
screen
strategi
applic
discoveri
small
molecul
modul
import
drug
target
sever
virtual
screen
studi
discuss
demonstr
success
applic
hierarch
virtual
screen
small
molecul
drug
discoveri
modern
drug
discoveri
process
start
identif
initi
hit
optim
improv
potenc
select
metabol
stabil
oral
bioavail
among
mani
way
identifi
initi
hit
drug
discoveri
highthroughput
screen
ht
virtual
screen
vs
common
vs
origin
develop
bring
cost
discov
new
molecul
use
ht
last
two
decad
advanc
comput
program
process
power
made
vs
import
tool
identifi
start
point
inhibitor
chemic
probe
variou
drug
discoveri
campaign
light
immens
potenti
vs
methodolog
identif
initi
hit
variou
structur
ligandbas
approach
develop
structurebas
method
reli
structur
inform
protein
target
typic
includ
method
molecular
dock
structurebas
pharmacophor
de
novo
design
ligandbas
method
work
absenc
structur
inform
protein
target
method
includ
two
threedimension
similar
search
ligandbas
pharmacophor
screen
machin
learn
approach
quantit
structur
activ
relationship
qsar
among
other
ligandbas
method
howev
requir
avail
least
one
known
activ
molecul
although
util
structur
ligandbas
method
individu
demonstr
immens
potenti
retriev
initi
hit
method
unabl
fulfil
practic
requir
drug
discoveri
alon
furthermor
everincreas
screen
librari
size
comput
cost
associ
vs
approach
especi
flexibl
molecular
dock
indispens
integr
differ
vs
approach
filter
compound
ligand
structurebas
method
combin
sequenti
parallel
manner
fig
common
way
combin
method
use
sequenti
funnel
like
manner
commonli
known
hierarch
vs
hlv
hlv
larg
small
molecul
librari
reduc
number
compound
small
enough
biolog
assay
appli
seri
filter
gener
two
three
sequenti
fig
contrast
hlv
parallel
virtual
screen
pv
sever
complementari
method
run
parallel
best
hit
rank
accord
method
select
biolog
test
fig
although
retrospect
analysi
literatur
data
shown
success
applic
pv
applic
real
world
scenario
could
found
paper
review
current
statu
commonli
use
hlv
approach
tri
understand
util
drug
http
elsevi
inc
right
reserv
discoveri
campaign
import
therapeut
target
although
scientif
literatur
inund
hierarch
comput
approach
protocol
restrict
review
studi
valid
experiment
assay
follow
section
outlin
type
hlv
approach
util
variou
small
molecul
discoveri
campaign
later
discuss
recent
case
success
hit
identif
util
hlv
protocol
final
describ
use
hlv
discov
inhibitor
import
drug
target
hierarch
combin
ligand
structurebas
vs
approach
gener
involv
sequenti
execut
dissimilar
vs
method
mostli
comput
inexpens
ligand
base
approach
similar
search
pharmacophor
screen
use
initi
step
hlv
protocol
method
demand
compar
high
comput
resourc
molecular
dock
molecular
dynam
md
simul
use
number
compound
screen
decreas
reason
number
final
step
major
hlv
campaign
incorpor
visual
select
compound
expert
research
commonli
known
cherri
pick
step
rank
vs
method
combin
expert
chemic
intuit
literaturebas
knowledg
hlv
classifi
three
categori
base
combin
vs
method
ligandbas
hlv
structurebas
hlv
hybrid
hlv
describ
detail
success
case
small
molecul
discoveri
use
three
class
hlv
summar
tabl
lbhlv
sequenti
combin
method
base
similar
search
compound
classif
similar
base
techniqu
includ
method
access
similar
one
experiment
identifi
hit
molecul
larg
librari
term
physicochem
properti
structur
fingerprint
electrostat
potenti
pharmacophor
featur
etc
compound
classif
techniqu
includ
cluster
machin
learn
base
method
bayesian
method
support
vector
machin
although
ligandbas
vs
method
use
either
standalon
combin
structurebas
vs
method
ligandbas
method
report
effect
combin
prospect
applic
yao
et
al
report
effici
multistep
ligandbas
vs
protocol
includ
physicochem
properti
filter
pharmacophorebas
screen
proteinligand
interact
fingerprint
similar
analysi
structur
similar
search
protocol
significantli
improv
hit
rate
compar
individu
method
among
prospect
applic
lbhlv
includ
combin
shapebas
vs
pharmacophor
model
use
temml
et
al
identifi
two
agonist
liver
x
receptor
report
agonist
activ
subtyp
liver
x
receptor
lxr
b
shape
similar
also
combin
electrostat
potenti
match
discoveri
melaninconcentr
hormon
receptor
antagonist
francisella
tularensi
enoylreductas
inhibitor
chemic
probe
nicotin
acid
adenin
dinucleotid
phosphat
naadp
anoth
applic
zinc
databas
subset
enrich
quinoxalin
scaffold
filter
base
pharmacokinet
properti
result
molecul
investig
pharmacophor
fingerprint
similar
known
quinoxalin
base
inhibitor
folat
cycl
protein
associ
biolog
assay
result
three
compound
interf
dihydrofol
reductas
thymidyl
synthas
reduc
level
levit
et
al
integr
molecular
descriptor
fingerprintbas
molecular
similar
ligandbas
pharmacophor
model
shapebas
vs
method
identifi
activ
human
bitter
tast
receptor
bayesian
analysi
use
pharmacophor
model
identifi
inhibitor
breast
cancer
resist
protein
bcrp
vs
carri
fdaapprov
drug
drug
found
exhibit
signific
effect
bcrp
transport
function
anoth
machin
learn
techniqu
support
vector
machin
svm
combin
fingerprint
similar
search
also
use
identif
molecular
probe
studi
cytohesin
ligandbas
method
advantag
comput
inexpens
abil
retriev
potent
hit
structurebas
method
howev
method
suffer
limit
bias
toward
activ
chemic
scaffold
therebi
gener
less
divers
hit
moreov
difficult
decid
right
input
queri
affect
qualiti
output
result
scenario
hierarch
combin
ligandbas
method
pharmacophor
model
similaritybas
method
assur
chemic
divers
potenc
structurebas
method
also
occasion
combin
hierarch
style
structurebas
method
use
standalon
combin
ligandbas
method
hierarch
combin
structurebas
method
suffer
limit
comput
expens
howev
recent
comput
develop
enabl
vs
execut
massiv
parallel
comput
architectur
allow
success
implement
cpu
intens
approach
flexibl
molecular
dock
md
simul
sbhlv
protocol
use
structurebas
method
hierarch
manner
group
identifi
compound
biaryl
urea
scaffold
inhibitor
small
ubiquitinlik
modifi
sumo
activ
protein
sumo
dock
small
molecul
librari
atp
bind
site
sumo
use
twostep
molecular
dock
strategi
initi
fast
rigid
protein
dock
use
dock
maybridg
small
molecul
librari
top
rank
compound
redock
use
method
incorpor
ligand
protein
flexibl
top
rank
hit
dock
subsequ
priorit
biolog
assay
use
md
simulationbas
bind
free
energi
calcul
similar
hierarch
dock
molecularmechan
poissonboltzmann
surfac
area
mmpbsa
score
procedur
also
use
identif
novel
tubulin
inhibitor
recent
kunz
et
al
report
low
molecular
weight
inhibitor
human
immunodefici
viru
proteas
subtyp
b
util
sbhlv
md
simul
use
identifi
transient
surfac
pocket
one
translat
structurebas
pharmacophor
queri
use
screen
compound
databas
molecular
dock
use
priorit
compound
biolog
assay
result
identif
two
activ
low
molecular
weight
inhibitor
apart
sequenti
combin
multipl
structurebas
approach
molecular
dock
base
vs
sometim
perform
multistep
hierarch
fashion
one
approach
implement
glide
program
start
coarsegrain
dock
follow
finer
level
sampl
strict
descript
score
function
hierarch
dock
approach
success
use
identifi
highli
potent
inhibitor
main
advantag
hierarch
dock
rapidli
screen
larg
small
molecul
librari
without
requir
high
perform
comput
infrastructur
fast
simpl
dock
method
reduc
big
librari
focus
set
compar
fewer
molecul
later
dock
use
comput
expens
method
hybrid
approach
combin
ligand
structurebas
hlv
lbsbhlv
commonli
use
among
three
type
hlv
lbsbhlv
hold
signific
potenti
take
advantag
avail
structur
ligand
inform
hit
identif
gener
fast
comput
approach
use
initi
follow
comput
expens
approach
histor
lbsbhlv
enjoy
success
either
lbhlv
sbhlv
recent
identif
serotonin
transport
ligand
excel
exampl
lbsbhlv
five
small
molecul
databas
screen
use
vs
workflow
combin
fingerprint
base
screen
admet
filter
pharmacophorebas
screen
molecular
dock
silico
screen
compound
test
use
vitro
screen
full
bind
assay
activ
compound
belong
structur
class
obtain
anoth
studi
hybrid
molecular
similar
approach
shaft
combin
dockingbas
vs
identifi
nine
low
lm
inhibitor
braf
analog
search
subsequ
chemic
optim
hit
result
compound
nm
potenc
diwu
et
al
also
employ
lbsbhlv
compris
bayesian
model
pharmacophor
model
molecular
dock
identifi
casein
kinas
inhibitor
nicola
et
al
prefilt
chembridg
compound
collect
druglik
subsequ
use
screen
four
pharmacophor
model
develop
known
activ
molecular
dock
use
priorit
list
compound
surfac
plasmon
reson
base
biolog
assay
extens
biolog
character
result
identif
compound
target
domain
coagul
factor
viii
activ
rang
lm
earlier
develop
lbsbhlv
workflow
util
protein
ligand
interact
inform
priorit
hit
ligand
structurebas
vs
workflow
employ
identifi
compound
potent
antitubercular
activ
anoth
excel
lbsbhlv
studi
liu
et
al
report
potent
inhibitor
insulinlik
growth
receptor
structurebas
pharmacophor
model
combin
molecular
dock
result
two
hit
inhibitori
activ
initi
hit
subject
substructur
search
retriev
structur
analog
priorit
use
pharmacophor
constrain
molecular
dock
subsequ
biolog
assay
identifi
hit
good
inhibitori
activ
implement
lbsbhlv
particularli
advantag
case
ligand
structur
inform
avail
take
account
possibl
inform
priorit
hit
biolog
assay
alreadi
establish
singl
structur
ligandbas
method
perform
well
target
hierarch
fusion
ligand
structur
base
method
improv
vs
perform
decreas
number
fals
posit
increas
true
posit
hit
molecular
dock
one
commonli
use
vs
method
central
compon
major
hlv
scheme
molecular
dock
algorithm
predict
orient
conform
ligand
respect
target
receptor
bind
site
hundr
bind
pose
gener
evalu
score
function
last
decad
wit
tremend
growth
develop
molecular
dock
methodolog
algorithm
program
method
adequ
use
protein
structur
inform
priorit
hit
biolog
assay
methodolog
effect
util
identifi
activ
hit
screen
librari
though
report
molecular
dock
fail
outperform
ligandbas
virtual
screen
method
even
presenc
protein
structur
inform
molecular
dock
program
quit
fast
abl
dock
small
librari
reason
amount
time
howev
dock
librari
million
compound
still
requir
huge
comput
resourc
effect
perform
massiv
parallel
comput
cluster
circumv
issu
hlv
approach
combin
molecular
dock
differ
level
filter
propos
speedup
time
consum
procedur
structurebas
vs
sever
approach
use
structur
similar
shape
electrostat
similar
ligand
filter
larg
screen
librari
other
util
ligand
structurebas
pharmacophor
model
reduc
larg
small
molecul
librari
reason
number
hundr
ten
thousand
compound
molecular
dock
follow
section
outlin
fast
vs
method
effect
combin
molecular
dock
similar
search
simpl
comput
inexpens
ligandbas
method
evalu
similar
librari
small
molecul
known
ligand
term
properti
similar
analysi
perform
use
topolog
indic
substructur
search
molecular
fingerprint
molecular
descriptor
shape
electrostat
properti
among
similar
measur
substructur
search
sometim
perform
screen
larg
ligand
librari
molecul
contain
defin
molecular
fragment
molecular
fingerprint
routin
use
filter
compound
molecular
dock
hlv
campaign
molecular
access
system
macc
fingerprint
one
popular
molecular
fingerprint
macc
fingerprint
success
integr
molecular
dock
sever
virtual
screen
studi
addit
macc
fingerprint
routin
use
improv
vs
hit
rate
identifi
structur
analog
hit
compound
extend
connect
fingerprint
accelri
tgd
two
tgt
pharmacophorebas
fingerprint
molecular
oper
environ
moe
fingerprint
commonli
combin
molecular
dock
sever
vs
studi
steric
complementar
ligand
receptor
one
key
factor
determin
strength
bind
form
basi
hypothesi
two
molecul
similar
shape
similar
biolog
activ
although
shape
similar
alon
suffici
retriev
highli
potent
binder
true
potenti
shape
similar
realiz
combin
molecular
dock
hierarch
manner
one
studi
acharya
et
al
screen
zinc
databas
coupl
roc
shape
base
approach
gold
dock
method
identifi
small
molecul
inhibitor
chemokin
receptor
n
terminu
bind
protein
xia
et
al
employ
hlv
protocol
combin
shapebas
approach
molecular
dock
discov
select
dehydrogenas
inhibitor
perform
vs
maybridg
databas
outlin
discoveri
process
novel
inhibitor
util
lbsbhlv
four
million
compound
small
molecul
librari
filter
base
shape
electrostat
similar
fragment
queri
prepar
conjug
ctermin
residu
substrat
protein
lysin
molecular
dock
priorit
hit
test
use
fret
base
assay
biolog
test
reveal
two
scaffold
later
optim
potenc
identifi
analog
identifi
seven
hit
show
ic
valu
lower
nm
salo
et
al
perform
vs
chembridg
librari
use
shapebas
filter
flexibl
dock
identifi
two
novel
scaffold
similar
vs
approach
also
use
identifi
novel
nonsteroid
fxr
ligand
pparc
partial
agonist
antitumor
agent
fungal
trihydroxynaphthalen
reductas
inhibitor
studi
instead
use
shapebas
similar
alon
molecular
dock
complement
approach
similar
search
electrostat
potenti
match
pharmacophor
model
alcaro
et
al
merg
compound
retriev
macc
fingerprint
roc
similar
search
use
seven
known
activ
druglik
filter
molecular
dock
use
priorit
compound
biolog
test
select
compound
result
compound
interact
human
telomer
gquadruplex
recent
group
identifi
novel
inhibitor
sumo
specif
proteas
util
vs
protocol
combin
shape
electrostat
potenti
base
similar
search
molecular
dock
inhibitor
discoveri
process
util
lbsbhlv
outlin
fig
similar
hlv
approach
also
use
identifi
inhibitor
biotin
carboxylas
f
tularensi
enoylreductas
anoth
studi
hamza
et
al
employ
vs
protocol
integr
pharmacophor
model
consensu
molecular
shape
pattern
activ
ligand
molecular
dock
identifi
inhibitor
lm
potenc
mycobacteri
mycosin
furthermor
wigger
et
al
develop
multistep
cascad
strategi
integr
shape
base
approach
molecular
dock
molecular
hologram
qsar
protocol
success
identifi
nonpeptid
cruzain
inhibitor
trypanocid
activ
recommend
intern
union
pure
appli
chemistri
iupac
term
pharmacophor
repres
ensembl
steric
electron
featur
necessari
ensur
optim
supramolecular
interact
specif
biolog
target
structur
trigger
block
biolog
respons
recent
year
sever
pharmacophor
model
approach
program
develop
pharmacophor
model
extens
use
drug
discoveri
either
standalon
vs
method
combin
vs
approach
molecular
dock
goal
identifi
inhibitor
matrix
metalloproteinas
pizio
et
al
creat
valid
sevenfeatur
pharmacophor
queri
base
cocryst
structur
queri
use
screen
librari
druglik
compound
molecular
dock
use
rankord
hit
pharmacophorebas
screen
enzym
inhibit
assay
reveal
nine
activ
compound
anoth
studi
novel
pkrlike
endoplasm
reticulum
kinas
perk
inhibitor
discov
use
hierarch
combin
pharmacophor
screen
molecular
dock
recent
similar
vs
protocol
use
identifi
inhibitor
sarscov
proteas
carbon
anhydras
vii
acetohydroxyacid
synthas
malari
cystein
proteas
protein
occasion
studi
combin
structur
ligand
base
pharmacophor
model
publish
use
complex
cocryst
structur
xue
et
al
built
structurebas
pharmacophor
model
refin
use
ligandbas
pharmacophor
model
consensu
model
use
screen
librari
compound
cascad
dock
priorit
hit
six
activ
compound
discov
ligand
receptor
base
pharmacophor
screen
combin
molecular
dock
also
use
discov
cxc
chemokin
receptor
antagonist
mitogenactiv
protein
kinas
inhibitor
pharmacophor
model
also
use
postfilt
tool
molecular
dock
result
order
discov
inhibitor
met
tyrosin
kinas
peach
et
al
util
seri
pharmacophor
queri
filter
dock
pose
form
critic
interact
voet
et
al
util
pharmacophor
model
preand
postfilt
tool
molecular
dock
vs
studi
identifi
novel
human
androgen
receptor
har
antagonist
first
creat
two
pharmacophor
queri
one
antagonist
agonist
base
har
ligand
cocryst
structur
homolog
model
pharmacophor
queri
use
filter
librari
commerci
avail
small
molecul
select
compound
fulfil
antagonist
queri
remov
match
agonist
queri
molecular
dock
pharmacophor
postfilt
visual
select
perform
select
compound
evalu
biolog
activ
studi
result
identif
two
novel
chemotyp
antagonist
activ
low
lm
rang
devoid
agonist
activ
describ
hierarch
combin
pharmacophor
model
molecular
dock
extens
exploit
drug
discoveri
howev
perform
hlv
scheme
highli
depend
upon
accuraci
pharmacophor
model
number
free
commerci
pharmacophor
model
program
includ
phase
moepharmacophor
ligandscout
gasp
catalyst
pharmid
etc
differ
pharmacophor
model
program
vari
perform
strength
weak
approach
consid
appli
hlv
protocol
advantag
shortcom
util
pharmacophor
model
method
drug
discoveri
report
sander
et
al
recent
advanc
high
perform
comput
allow
implement
comput
demand
precis
method
flexibl
molecular
dock
molecular
dynam
simul
vs
tool
success
vs
protocol
depend
accur
model
proteinligand
interact
requir
consider
protein
ligand
dynam
environ
sever
methodolog
develop
account
protein
flexibl
includ
soft
dock
sampl
sidechain
rotam
librari
dock
ensembl
receptor
conform
molecular
dock
combin
md
simul
especi
recommend
md
simul
use
gener
ensembl
protein
conform
molecular
dock
moreov
md
simul
free
energi
base
rank
util
priorit
molecular
dock
hit
strategi
effect
use
hlv
scheme
identif
potent
inhibitor
wang
et
al
carri
dockingbas
vs
use
md
simul
gener
ensembl
protein
conform
md
simul
optim
dock
complex
led
select
compound
test
human
aldos
reductas
inhibit
final
vitro
assay
identifi
two
submicromolar
compound
novel
chemotyp
apart
gener
receptor
ensembl
molecular
dock
md
simul
also
use
identifi
function
relev
receptor
conform
eg
inact
dfgout
conform
kinas
achiev
select
variou
kinas
activ
state
gpcr
identif
agonist
receptor
conform
employ
correspond
hlv
campaign
hu
et
al
report
f
tularensi
fabi
inhibitor
identifi
hlv
protocol
integr
molecular
dock
md
simul
studi
around
hit
dockingbas
vs
subject
short
md
simul
implicit
solvent
mmpbsa
bind
free
energi
use
rankord
compound
hit
singl
biolog
assay
reveal
activ
hit
use
similar
approach
group
also
success
identifi
inhibitor
sumo
protein
anoth
studi
cao
et
al
discov
novel
tubulin
inhibitor
take
advantag
hlv
protocol
select
nine
compound
biolog
assay
screen
inhous
librari
around
compound
sequenti
use
molecular
dock
md
simul
base
mmpbsa
bind
free
energi
calcul
five
compound
demonstr
tubulin
inhibitori
activ
effici
take
advantag
mmpbsa
bind
free
energi
base
rank
comput
inexpens
vs
methodolog
develop
studi
reduc
time
requir
calcul
mmpbsa
bind
free
energi
energi
minim
singl
structur
strategi
success
integr
molecular
dock
hlv
scheme
result
identif
potent
inhibitor
plasmepsin
ii
kinas
although
integr
molecular
dock
molecular
dynam
simul
bind
free
energi
calcul
seem
attract
option
due
precis
handl
proteinligandsolv
interact
still
limit
challeng
one
obviou
need
requir
huge
comput
resourc
facilit
adequ
sampl
accur
free
energi
calcul
apart
comput
requir
forc
field
use
molecular
dynam
simul
approxim
need
refin
calcul
bind
free
energi
use
rel
fast
method
mmpbsa
rescor
reli
ligand
start
pose
predict
molecular
dock
wrong
start
pose
may
lead
erron
result
rescor
dock
pose
suggest
possibl
solut
achiev
good
accuraci
recent
advanc
discoveri
small
molecul
proteinprotein
interact
inhibitor
smppii
made
modul
proteinprotein
interact
ppi
achiev
vs
approach
play
signific
role
chang
notion
undrugg
ppi
sever
exampl
vs
studi
report
literatur
target
ppi
includ
domain
uparupa
tetramer
annexin
sumosim
ifnaifnar
hiv
vs
studi
took
advantag
hierarch
approach
identifi
initi
hit
later
optim
highli
potent
smppii
lbsbhlv
employ
studi
studi
report
sbhlv
approach
substructur
search
combin
molecular
dock
use
identifi
compound
disrupt
interact
aminopeptidas
n
christ
et
al
present
excel
exampl
employ
lbsbhlv
identif
smppii
interact
util
pharmacophorebas
screen
molecular
dock
pharmacophor
postfilt
select
divers
molecul
biolog
assay
optim
initi
hit
first
test
analog
medicin
chemistri
led
identif
compound
potenc
low
lm
rang
use
similar
lbsbhlv
approach
compris
pharmacophor
screen
molecular
dock
reddi
et
al
identifi
substitut
inhibitor
annexin
ppi
voet
et
al
translat
ppi
sumo
sumo
interact
motif
sim
pharmacophor
queri
queri
use
screen
small
molecul
librari
result
compound
priorit
use
molecular
dock
pharmacophor
postfilt
multipl
biolog
assay
hsqcnmr
reveal
low
lm
inhibitor
sumosim
ppi
betzi
et
al
appli
druglik
filter
dock
pharmacophor
filter
identifi
inhibitor
hiv
interact
potenc
lm
rang
furthermor
novel
smppii
interact
identifi
use
hlv
scheme
compris
pharmacophor
model
molecular
dock
promis
compound
report
studi
disrupt
interact
vitro
lm
interact
target
smppii
discoveri
time
util
sbhlv
approach
glide
hierarch
dock
protocol
use
identifi
nine
hit
three
novel
scaffold
anoth
studi
lavecchia
et
al
built
theoret
model
frataxinubiquitin
complex
reveal
potenti
ubiquitinbind
site
frataxin
interfac
use
perform
hierarch
dockingbas
vs
result
identif
one
compound
prevent
frataxin
ubiquitin
degrad
subsequ
scaffold
search
identifi
seri
compound
abl
disrupt
frataxinubiquitin
ppi
lm
affin
similar
hierarch
dock
approach
also
use
identifi
inhibitor
ppi
use
sbhlv
khanna
et
al
report
discoveri
smppii
inhibit
uparupa
ppi
compound
biolog
assay
select
util
multistep
dockingbas
vs
perform
conform
ensembl
upar
sampl
md
simul
extens
biochem
character
reveal
compound
inhibit
uparupa
ppi
ic
lm
sbhlv
studi
hu
et
al
employ
induc
fit
dock
mmgbsa
rescor
identifi
compound
target
inledgf
ppi
two
potent
compound
display
ic
valu
lm
g
proteincoupl
receptor
gpcr
constitut
largest
famili
membran
protein
import
target
treatment
variou
diseas
gpcr
subject
mani
vs
studi
sever
vs
studi
report
gpcr
modul
follow
hierarch
multistep
protocol
larg
small
molecul
librari
filter
smaller
set
test
variou
assay
due
unavail
crystal
structur
gpcr
major
hlv
carri
use
homolog
model
tikhonova
et
al
use
structur
model
free
fatti
acid
receptor
perform
vs
employ
similar
search
pharmacophor
search
molecular
dock
biolog
assay
compound
reveal
compound
act
either
antagonist
agonist
engel
et
al
creat
structurebas
pharmacophor
describ
interact
potenti
within
thyrotropinreleas
hormon
trh
receptor
bind
pocket
zinc
small
molecul
librari
screen
result
compound
priorit
assay
use
flexibl
molecular
dock
molecular
descriptor
five
structur
divers
antagonist
trh
receptor
identifi
recent
use
multipl
crystal
structur
templat
yoshikawa
et
al
develop
homolog
model
valid
homolog
model
util
vs
employ
molecular
dock
pharmacophor
postfilt
studi
result
ligand
novel
scaffold
ic
rang
lm
anoth
recent
report
dynam
pharmacophor
model
molecular
dock
use
discov
agonist
serotonin
receptor
subtyp
r
homolog
model
r
base
activ
state
adrenerg
receptor
use
vs
furthermor
de
graaf
et
al
appli
lbsbhlv
identifi
modul
glucagon
receptor
glr
glucagonlik
peptid
receptor
glr
challeng
target
belong
class
b
gpcr
librari
million
druglik
compound
filter
base
structur
similar
known
antagonist
subsequ
hit
dock
transmembran
caviti
glr
homolog
model
final
select
biolog
assay
util
proteinligand
interact
inform
two
evalu
compound
display
vitro
bind
glr
inhibit
glucagon
effect
interestingli
one
compound
inact
glr
show
vitro
bind
lin
et
al
combin
homolog
model
molecular
dock
md
simul
establish
kinas
inhibitor
sorafenib
nanomolar
antagonist
receptor
success
studi
discov
gpcr
modul
perform
hlv
virtual
screen
homolog
model
includ
report
adrenerg
receptor
receptor
nonpeptid
receptor
recent
advanc
crystallographi
gpcr
open
excel
opportun
structurebas
vs
studi
major
studi
util
molecular
dock
vs
tool
studi
appli
hlv
approach
crystal
structur
includ
discoveri
histamin
h
receptor
adrenoreceptor
adenosin
receptor
sphingosin
receptor
ligand
among
studi
de
graaf
et
al
develop
valid
hlv
method
combin
molecular
dock
interact
fingerprint
ifp
base
score
method
success
appli
identif
human
histamin
h
receptor
ligand
potenc
rang
lm
nm
anoth
studi
sander
et
al
combin
ligand
structurebas
method
carri
prospect
vs
three
gpcr
adrenoreceptor
adenosin
receptor
sphingosin
receptor
biolog
assay
reveal
activ
ligand
adrenoreceptor
adenosin
receptor
sphingosin
receptor
respect
describ
major
hlv
effort
focus
identif
small
molecul
modul
class
rhodopsinlik
gpcr
reason
may
avail
plenti
ligand
inform
ever
increas
crystal
structur
class
receptor
bar
studi
hlv
exploit
discoveri
small
molecul
modul
class
b
c
gpcr
may
due
unavail
suffici
structur
inform
receptor
transmembran
domain
howev
recent
avail
transmembran
domain
crystal
structur
class
b
class
c
gpcr
augment
drug
discoveri
effort
special
develop
fuel
effort
exploit
power
lbsbhlv
discoveri
small
molecular
modul
class
b
c
gpcr
wit
tremend
growth
success
applic
vs
variou
drug
discoveri
campaign
recent
year
vs
method
reli
ligand
structurebas
approach
develop
success
employ
prospect
applic
order
enhanc
vs
effici
improv
hit
rate
integr
sever
ligand
structurebas
approach
suggest
survey
recent
publish
vs
studi
reveal
hierarch
combin
common
way
integr
ligand
structurebas
method
mostli
comput
inexpens
ligandbas
method
use
begin
multistep
hierarch
procedur
comput
demand
method
use
toward
end
pharmacophor
model
molecular
dock
two
extens
employ
vs
method
hlv
scheme
hierarch
combin
two
method
proven
effect
discoveri
inhibitor
difficult
drug
target
ppi
gpcr
anoth
class
import
drug
target
hlv
shown
potenti
retriev
promis
hit
especi
consid
recent
advanc
gpcr
crystallographi
